Spots Global Cancer Trial Database for breakthrough pain
Every month we try and update this database with for breakthrough pain cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent | NCT02836379 | Breakthrough Pa... | No intervention | 18 Years - | Angelini Farmacéutica | |
| Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM) | NCT03435120 | Breakthrough Pa... | No intervention | 18 Years - | Angelini Farmacéutica | |
| Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis | NCT02050503 | Breakthrough Pa... Mucositis Radiotherapy Chemotherapy Head and Neck C... | 18 Years - 75 Years | Grupo de Investigación Clínica en Oncología Radioterapia | ||
| Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients | NCT00842829 | Cancer Pain Breakthrough Pa... | Fentanyl Buccal... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| An Open Label Study to Evaluate Safety, Tolerability and Clinical Utility of ULTRACET® (37.5mg Tramadol Hydrochloride/325mg Acetaminophen) for the Treatment of Breakthrough Pain in Cancer Patients | NCT00576173 | Pain | tramadol hydroc... | 18 Years - | Johnson & Johnson Taiwan Ltd | |
| Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units | NCT02840500 | Breakthrough Pa... | No intervention | 18 Years - | Angelini Farmacéutica | |
| Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment | NCT02437929 | Breakthrough Pa... Pain Due to Cer... Pain Cancer Terminal Diseas... | Mobilization Positioning Personal Hygien... Bladder cathete... Wound care Subcutaneous dr... | 18 Years - | Antea Foundation | |
| Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment | NCT02437929 | Breakthrough Pa... Pain Due to Cer... Pain Cancer Terminal Diseas... | Mobilization Positioning Personal Hygien... Bladder cathete... Wound care Subcutaneous dr... | 18 Years - | Antea Foundation | |
| Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients | NCT00263575 | Pain Cancer | EN3267 | 17 Years - | Kyowa Kirin Co., Ltd. | |
| Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP) | NCT00236041 | Cancer Breakthrough Pa... | ACTIQ® | 3 Years - 15 Years | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy | NCT02869321 | Gastrostomy Breakthrough Pa... Upper Aerodiges... | Fentanyl Morphine Sulfat... Fentanyl placeb... Morphine Sulfat... Gastrostomy | 18 Years - | Central Hospital, Nancy, France | |
| Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment | NCT02437929 | Breakthrough Pa... Pain Due to Cer... Pain Cancer Terminal Diseas... | Mobilization Positioning Personal Hygien... Bladder cathete... Wound care Subcutaneous dr... | 18 Years - | Antea Foundation | |
| Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients | NCT00263575 | Pain Cancer | EN3267 | 17 Years - | Kyowa Kirin Co., Ltd. | |
| Sublingual Methadone for the Management of Cancer Breakthrough Pain | NCT00125294 | Cancer Pain | Methadone | 18 Years - | AHS Cancer Control Alberta | |
| Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years | NCT00994760 | Breakthrough Pa... Cancer | Instanyl (Intra... | 18 Years - | Takeda | |
| Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients | NCT00842829 | Cancer Pain Breakthrough Pa... | Fentanyl Buccal... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain | NCT00236145 | Breakthrough Pa... | ACTIQ (Oral tra... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement | NCT05053308 | Cancer Pain Breakthrough Pa... | Intravenous Inf... Sublingual Tabl... | 19 Years - 80 Years | Seoul National University | |
| Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain | NCT00236145 | Breakthrough Pa... | ACTIQ (Oral tra... | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer | NCT01842893 | Breakthrough Pa... Cancer | Fentanyl Ethyph... | 18 Years - | Ethypharm | |
| Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients | NCT00263575 | Pain Cancer | EN3267 | 17 Years - | Kyowa Kirin Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
